HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kratom Suspected In 35-State Salmonella Outbreak: Health And Wellness Industry News

This article was originally published in The Rose Sheet

Executive Summary

Kratom suspected in 35-state salmonella outbreak; FTC mails refunds for false weight loss ads; Spear at tip of Nutrition 21 sales; and BioCell Collagen halal certified.

You may also be interested in...



Kratom Industry Group Has First Qualifier For Its GMP Standards Exceeding FDA's

Online retailer and supplement brand Kraken Kratom is first business American Kratom Association recognized with its GMP Qualified Vendor status. But, FDA reiterates kratom should not be used in supplements until an NDI notification is submitted showing a reasonable expectation of safety for its intended use, and DEA still has pending a proposed order to schedule kratom constituent ingredients as controlled substances.

Las Vegas Kratom Marketer Rolls Dice On FDA's Mandatory Recall Authority

FDA for the first time exercises its mandatory recall authority over food and supplement products to order Triangle Pharmanaturals, which opened for business in Las Vegas in April 2017, to recall all of the kratom-containing products it has distributed and to cease distributing additional products.The agency also notes in the announcement that it continues to scrutinize kratom's safety unrelated to contamination.

Kratom Advocates Urge Industry Compliance, FDA And DEA Compassion

Now that FDA has completed its evaluations of two compounds in kratom – mitragynine and 7-hydroxymitragynine – that DEA has proposed to schedule as controlled substances, researchers who attest to the ingredient's safety and its value in helping opioid abusers through withdrawal or as a natural pain reliever or mood enhancer say time could be running short to convince federal officials against ending consumer access to kratom products due to fear that the ingredient is an opioid.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel